<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260246</url>
  </required_header>
  <id_info>
    <org_study_id>R-10-533</org_study_id>
    <secondary_id>17389</secondary_id>
    <nct_id>NCT01260246</nct_id>
  </id_info>
  <brief_title>Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes</brief_title>
  <official_title>Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial evaluating the impact of
      sitagliptin therapy in patients with concomitant type 2 diabetes and non-alcoholic
      steatohepatitis (NASH) on improving liver disease based on biopsy results. The effect of
      sitagliptin on other measures such as hormones modifying insulin release and sensitivity
      (termed adipocytokines), fat distribution, and biomarkers of cardiovascular risk will also be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate improvement in liver disease (based on liver biopsy)with sitagliptin.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In individuals with NASH and DM2: To document the impact of sitagliptin therapy on adipocytokines, inflammatory markers, non-traditional cardiovascular risk factors, adipose distribution, and dyslipidemia.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In individuals with NASH and DM2: To delineate the effect of sitagliptin therapy on platelet aggregation and oxidative stress.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In individuals with NASH and DM2: To determine the correlation between changes in histology with changes in hepatic fat demonstrated by MRI and changes in fibrosis by Fibroscan.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sitagliptin 100mg/daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo match for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>pill, 100mg/daily for 6 months</description>
    <arm_group_label>sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo match for 6 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known DM2 (receiving lifestyle management and/or metformin and/or sulfonylurea

          -  Stable therapy for DM2 for the past 3 months

          -  All other medications and doses stable for past 3 months

          -  HbA1c 8.9% or lower (can be done in past 30 days)

          -  Known NASH based on the accepted American Gastroenterological Association Criteria:

               1. Alcohol consumption (&lt; 10g/day in women and &lt;20g/day in men)

               2. Cause of liver disease other than NAFLD (negative investigations for: viral
                  hepatitis, iron overload, a-1 antitrypsin, ceruloplasmin, autoimmune disease)

               3. Liver histology demonstrating macrovesicular fatty change of hepatocytes, with
                  evidence of steatohepatitis, manifested by the presence of Mallory Bodies,
                  ballooning degeneration, lobular neutrophilic inflammation and perisinusoidal
                  fibrosis. (If liver biopsy done within 2 years prior to screening for this trial,
                  that biopsy will be reviewed to ensure it meets criteria for diagnosis).

        Exclusion Criteria:

          -  Any contraindication for undergoing MRI

          -  Child class B or C cirrhosis

          -  Participation in another clinical trial

          -  Use of thiazoledinedione (rosiglitazone or pioglitazone) in past 6 months

          -  Current use of plavix

          -  Previous exposure to sitagliptin

          -  Prior history of pancreatitis

          -  History of anaphylaxis to another Canadian-marketed DPP-IV inhibitor (saxagliptin)

          -  Creatine clearance &lt;30 ml/min

          -  Anaemia (haemoglobin &lt; 110 mg/dL)

          -  Platelet count &lt; 50 000 cells/mm3

          -  Known heart or kidney failure

          -  Comorbid condition that decreases natural life span (e.g. known cancer)

          -  Pregnant or breastfeeding or wishing to become pregnant in the next 6 months

          -  Current or past treatment with medications that can induce steatohepatitis (e.g.
             glucocorticoids, methotrexate, amiodarone etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tisha Joy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Health Care, UWO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Tisha Joy</investigator_full_name>
    <investigator_title>Assistant Professor, Division of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

